JP2013543501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543501A5 JP2013543501A5 JP2013532213A JP2013532213A JP2013543501A5 JP 2013543501 A5 JP2013543501 A5 JP 2013543501A5 JP 2013532213 A JP2013532213 A JP 2013532213A JP 2013532213 A JP2013532213 A JP 2013532213A JP 2013543501 A5 JP2013543501 A5 JP 2013543501A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013691 Interleukin-17 Human genes 0.000 claims 62
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 16
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 16
- 201000004681 Psoriasis Diseases 0.000 claims 12
- 230000006698 induction Effects 0.000 claims 11
- 238000012423 maintenance Methods 0.000 claims 9
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 4
- 239000000710 homodimer Substances 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229960005339 acitretin Drugs 0.000 claims 1
- 229960002459 alefacept Drugs 0.000 claims 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39138810P | 2010-10-08 | 2010-10-08 | |
| US61/391,388 | 2010-10-08 | ||
| PCT/EP2011/067522 WO2012045848A1 (en) | 2010-10-08 | 2011-10-07 | Methods of treating psoriasis using il-17 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013253745A Division JP2014114288A (ja) | 2010-10-08 | 2013-12-09 | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543501A JP2013543501A (ja) | 2013-12-05 |
| JP2013543501A5 true JP2013543501A5 (cg-RX-API-DMAC7.html) | 2014-03-27 |
| JP5537740B2 JP5537740B2 (ja) | 2014-07-02 |
Family
ID=44759699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532213A Active JP5537740B2 (ja) | 2010-10-08 | 2011-10-07 | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 |
| JP2013253745A Withdrawn JP2014114288A (ja) | 2010-10-08 | 2013-12-09 | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013253745A Withdrawn JP2014114288A (ja) | 2010-10-08 | 2013-12-09 | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 |
Country Status (28)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| SG10201604093XA (en) | 2010-01-15 | 2016-07-28 | Kirin Amgen Inc | Antibody formulation and therapeutic regimens |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| CN104800844A (zh) | 2010-11-05 | 2015-07-29 | 诺华有限公司 | 使用il-17拮抗剂治疗类风湿性关节炎的方法 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| US20150064193A1 (en) * | 2011-11-21 | 2015-03-05 | Novartis Ag | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles |
| WO2014143540A1 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| SG10201804954UA (en) * | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| EP3033107A1 (en) * | 2013-08-15 | 2016-06-22 | Novartis AG | Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists |
| US11421025B2 (en) | 2013-12-27 | 2022-08-23 | Osaka University | Treatment of IL-17A diseases |
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| MY184189A (en) * | 2014-03-31 | 2021-03-24 | Amgen K A Inc | Methods of treating nail and scalp psoriasis |
| CA3198322A1 (en) | 2014-05-15 | 2015-11-19 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) * | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| SG11201701276SA (en) * | 2014-08-26 | 2017-03-30 | Kirin Amgen Inc | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
| DK3191120T3 (da) | 2014-09-10 | 2024-07-15 | Novartis Ag | Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| ES3000557T3 (en) | 2015-03-02 | 2025-02-28 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| RU2754683C2 (ru) | 2015-10-27 | 2021-09-06 | Юсб Биофарма Срл | Способы лечения с использованием анти-il-17a антител |
| EP4477265A3 (en) | 2016-07-19 | 2025-03-19 | Novartis AG | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |
| JP2019505516A (ja) * | 2016-11-28 | 2019-02-28 | ノバルティス アーゲー | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |
| WO2018158741A1 (en) * | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
| WO2019040230A1 (en) * | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | TREATMENT OF GENITAL PSORIASIS |
| TWI725532B (zh) * | 2018-09-11 | 2021-04-21 | 美商美國禮來大藥廠 | 治療牛皮癬之方法 |
| CN114127108A (zh) | 2019-07-30 | 2022-03-01 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
| KR20220066318A (ko) | 2019-09-20 | 2022-05-24 | 노파르티스 아게 | 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법 |
| WO2022127842A1 (zh) * | 2020-12-17 | 2022-06-23 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| WO2023186174A1 (en) * | 2022-04-01 | 2023-10-05 | Zai Lab (Shanghai) Co., Ltd. | Topical formulation comprising an il-17a binding molecule and uses thereof |
| CN116593718B (zh) * | 2023-07-18 | 2023-09-15 | 军科正源（北京）药物研究有限责任公司 | 用于检测司库奇尤单抗抗药性抗体的试剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| US6093745A (en) * | 1997-11-25 | 2000-07-25 | Psorx, L.L.C. | Methods and composition for treating skin proliferative diseases |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| RS51142B (sr) * | 2005-09-01 | 2010-10-31 | Schering Corporation | Primena antagonista il-23 i il-17 za lečenje autoimunog okularnog zapaljenskog oboljenja |
| EP1963368B3 (en) | 2005-12-13 | 2020-06-10 | Eli Lilly And Company | Anti-il-17 antibodies |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| RU2367429C2 (ru) | 2007-01-30 | 2009-09-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Способ лечения псориаза |
| EP2152318A4 (en) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| RU2341272C1 (ru) | 2007-10-22 | 2008-12-20 | Левон Никитович Мкртчян | Средство для неспецифической иммунотерапии |
| WO2010034443A1 (en) * | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
-
2011
- 2011-10-07 LT LTEP11764764.4T patent/LT2625199T/lt unknown
- 2011-10-07 SG SG2013018486A patent/SG188979A1/en unknown
- 2011-10-07 EP EP20187002.9A patent/EP3792281A1/en not_active Ceased
- 2011-10-07 TW TW100136608A patent/TWI548419B/zh active
- 2011-10-07 CN CN201710261381.2A patent/CN107029234A/zh active Pending
- 2011-10-07 HR HRP20180301TT patent/HRP20180301T1/hr unknown
- 2011-10-07 HU HUE11764764A patent/HUE038334T2/hu unknown
- 2011-10-07 NO NO11764764A patent/NO2625199T3/no unknown
- 2011-10-07 PH PH1/2013/500660A patent/PH12013500660B1/en unknown
- 2011-10-07 EP EP25216056.9A patent/EP4670788A2/en active Pending
- 2011-10-07 SI SI201131408T patent/SI2625199T1/en unknown
- 2011-10-07 TW TW105116323A patent/TWI564022B/zh active
- 2011-10-07 US US13/876,367 patent/US9717791B2/en active Active
- 2011-10-07 EP EP11764764.4A patent/EP2625199B1/en active Active
- 2011-10-07 KR KR1020147018691A patent/KR101620771B1/ko active Active
- 2011-10-07 WO PCT/EP2011/067522 patent/WO2012045848A1/en not_active Ceased
- 2011-10-07 KR KR1020137011792A patent/KR20130110179A/ko not_active Ceased
- 2011-10-07 MX MX2013003916A patent/MX356279B/es active IP Right Grant
- 2011-10-07 CA CA2813900A patent/CA2813900C/en active Active
- 2011-10-07 AU AU2011311482A patent/AU2011311482B2/en active Active
- 2011-10-07 EP EP17195148.6A patent/EP3299390A1/en not_active Withdrawn
- 2011-10-07 EP EP22186296.4A patent/EP4137514A1/en active Pending
- 2011-10-07 RU RU2013120957/15A patent/RU2591083C2/ru active
- 2011-10-07 ES ES11764764.4T patent/ES2660770T3/es active Active
- 2011-10-07 BR BR112013008501A patent/BR112013008501A2/pt active Search and Examination
- 2011-10-07 JP JP2013532213A patent/JP5537740B2/ja active Active
- 2011-10-07 PL PL11764764T patent/PL2625199T3/pl unknown
- 2011-10-07 PT PT117647644T patent/PT2625199T/pt unknown
- 2011-10-07 CN CN2011800487322A patent/CN103154031A/zh active Pending
- 2011-10-07 RU RU2016120615A patent/RU2665954C1/ru active
- 2011-10-07 DK DK11764764.4T patent/DK2625199T3/en active
- 2011-10-07 KR KR1020147036815A patent/KR20150018595A/ko not_active Withdrawn
-
2013
- 2013-03-18 IL IL225310A patent/IL225310A/en active IP Right Grant
- 2013-04-05 CL CL2013000930A patent/CL2013000930A1/es unknown
- 2013-05-03 MA MA35872A patent/MA34646B1/fr unknown
- 2013-12-09 JP JP2013253745A patent/JP2014114288A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,577 patent/US10583190B2/en active Active
-
2018
- 2018-02-22 CY CY20181100220T patent/CY1119942T1/el unknown
- 2018-06-01 HK HK18107225.2A patent/HK1247932A1/en unknown
-
2019
- 2019-12-19 US US16/720,351 patent/US11534490B2/en active Active
-
2020
- 2020-12-18 US US17/127,738 patent/US20210113688A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,724 patent/US20210162044A1/en not_active Abandoned
-
2022
- 2022-12-02 US US18/061,227 patent/US20230321231A1/en active Pending
-
2024
- 2024-12-16 US US18/983,034 patent/US20250161444A1/en active Pending
- 2024-12-16 US US18/983,037 patent/US20250161445A1/en active Pending
- 2024-12-16 US US18/983,030 patent/US20250161443A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543501A5 (cg-RX-API-DMAC7.html) | ||
| JP2014114288A5 (cg-RX-API-DMAC7.html) | ||
| US10485844B2 (en) | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor | |
| RU2013120957A (ru) | Способы лечения псориаза с использованием антагонистов il-17 | |
| JP2020002172A5 (cg-RX-API-DMAC7.html) | ||
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| JP2016065094A5 (cg-RX-API-DMAC7.html) | ||
| JP2008535841A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515493A5 (cg-RX-API-DMAC7.html) | ||
| CN109963577B (zh) | 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法 | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2014515763A5 (cg-RX-API-DMAC7.html) | ||
| JP2015530867A5 (cg-RX-API-DMAC7.html) | ||
| JP2012102122A5 (cg-RX-API-DMAC7.html) | ||
| JP2023520676A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 | |
| JP2015525798A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502219A5 (cg-RX-API-DMAC7.html) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| CN101878037A (zh) | 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途 | |
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| JP2019519584A5 (cg-RX-API-DMAC7.html) | ||
| BR112020017445A2 (pt) | anticorpos anti cd6 para tratar asma severa | |
| US20230265168A1 (en) | Antibody binding to hepatitis b virus surface antigen and application of antibody | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 |